Hangzhou Tigermed Consulting Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) Stock Overview
Explore Hangzhou Tigermed Consulting Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
5.7B
P/E Ratio
74.39
EPS (TTM)
$0.15
ROE
0.02%
HNGZY Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $2.48.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 74.39 and a market capitalization of 5.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Xiaoping Ye D.Phil, EMBA,
10,185
F18, Building A – Shengda Science Park, Hangzhou
2022